USE OF DIFFERENT DOSES OF ANTI-Rh IgG IN THE PREVENTION OF Rh ISOIMMUNISATION

Buchanan, Donald I.; Beck, R; Bell, R. Edward; Taylor, Walter C.

doi:10.1016/s0140-6736(69)90053-1

Cited by 18 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the point of view of both mother and the community it is immaterial whether antibodies are formed after the administration of anti-D immunoglobulin or before. The Canadians and the Australians have already paid attention to both groups (Zipursky and Israels, 1967;Buchanan et al, 1969;Bowman, 1970;N. G. Davey in J7ournal of Reproductive Medicine, 1971); however, in many series little or no interest has been devoted to the group of mothers in whom antibodies were present before anti-D immunoglobulin was administered.…”

Section: Control Seriesmentioning

confidence: 99%

“…The possible boosting effect of an additional Rh-positive child during the next pregnancy has so far only been studied in rather limited series (Woodrow, 1970;Schneider, 1971;Woodrow et al, 1971). With a few exceptions (Zipursky and Israels, 1967;Godel et al, 1968;Buchanan et al, 1969; V. J. Freda and J. G. Gorman in Journal of Reproductive Medicine, 1971) the reports pay little or no attention to the group of patients excluded from prevention due to antibody formation before the delivery.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Rh Prevention: A Report and Analysis of a National Programme

Eklund¹,

Nevanlinna²

1973

Journal of Medical Genetics

View full text Add to dashboard Cite

Section: Control Seriesmentioning

confidence: 99%

mentioning

confidence: 99%

Rh Prevention: A Report and Analysis of a National Programme

Eklund¹,

Nevanlinna²

1973

Journal of Medical Genetics

View full text Add to dashboard Cite

“…Because of the risk of priming during a first pregnancy Canadian workers have been, and are now, treating women during the third trimester (Zipursky and Israels, 1967;Buchanan et al, 1969;Bowman, 1970). We await the results of the extensive Manitoba trial with interest.…”

Section: Discussionmentioning

confidence: 99%

Prevention of Rh-haemolytic Disease: Results of the Liverpool "Low-risk" Clinical Trial

Woodrow¹,

Clarke²,

McConnell³

et al. 1971

BMJ

View full text Add to dashboard Cite

SummaryA clinical trial is reported in which Rh-negative primiparae, just delivered of an Rh-positive ABO-compatible infant and in whom fetal cell counts after delivery suggested less than 02 ml of circulating fetal blood, were treated with about 200 jig of anti-D gammaglobulin.Three (0 36%) out of 844 women thus treated developed anti-D in the subsequent six months; this is 10% of the incidence in untreated controls. Three (1-8%) out of 171 treated mothers had anti-D at the end of the second Rh-positive pregnancy, and this is 18% of the incidence in controls.Possible reasons for the occasional failure of the treatment are discussed and the results of this trial are compared with those of a previous trial in which 1,000 jig or more of anti-D was given to a different group of mothers. The combined results of the two trials lead to the conclusion that the passive administration of anti-D gammaglobulin after delivery affords in this population of Rh-negative women a 95% protection rate in the postdelivery period and an 89% protection rate by the end of the subsequent pregnancy. IntroductionIn our report of a clinical trial to test the effectiveness of about 1,000 F±g of anti-D gammaglobulin in preventing Rh immunization of Rh-negative primiparae (Combined Study, 1966) it was noted that a further trial had been initiated in Liverpool. The plan of this second one was to treat mothers showing less than an estimated 0-2 ml of Rh-positive fetal blood in their circulation after delivery with about 200 Fg of anti-D gammaglobulin. The results of this trial are presented here and some implications discussed.

show abstract

“…Originally, in the application of this technique there was believed to be a risk that higher doses of antibody within pregnancy could cause erythroblastosis fetalis iatrogenically (Loke, 1978), and therefore intrapartum doses of anti-Rh antibody (145 wg; Buchanan et al, 1969) remained lower than those used postpartum (200-300 pg). It might be possible to increase these doses in the first trimester and to eliminate the group of conditions in which the anti& dose is thought to be inadequate to prevent sensitization by erythrocytes during blood-mixing events occurring early in pregnancy.…”

Section: Eyriiimentioning

confidence: 99%